drugset / Trial / NCT02179268

Antidepressants and Bone Mineral Density

NCT02179268

Phase 3 Completed 203 enrolled Guiyang Medical University
RandomizedSingle-groupOpen-labelSupportive care

Summary

The aim of this five arm randomized trial was thus to compare selective serotonin reuptake inhibitor (SSRI)sertraline and citalopram to a dual reuptake inhibitor venlafaxine, a nor-adrenaline reuptake inhibitor reboxetine and a control group receiving placebo, with the primary endpoint being bone mineral density, and secondary endpoints being bone turnover markers.

Timeline

Start
2012-03
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Citalopram Small molecule 20 mg Oral
Comparator Reboxetine Unknown 4 mg
Comparator Sertraline Small molecule 50 mg
Comparator Venlafaxine Small molecule 25 mg

Indications